Navigation Links
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
Date:8/3/2009

DALLAS, Aug. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on its clinical development strategy for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumors in human clinical studies. Access has commenced a new clinical study of ProLindac in France. The study will examine dose levels and regimens of ProLindac monotherapy in cancer patients, provide additional data to support design of combinations studies, and extend the safety database. Two ovarian cancer patients have been enrolled in the study to date, and it is anticipated 6 to 12 patients will be enrolled this year in advance of enrolling patients in trial evaluating ProLindac in combination with other chemotherapies. Access recently announced data from a recurrent ovarian cancer trial that showed that ProLindac was more active than currently available platinum drugs in that patient population, and that the drug was very well tolerated.

ProLindac is a novel DACH platinum drug that has shown to be active in many solid tumors in human clinical studies. Platinum drugs are one of the most clinically and commercially successful class of chemotherapies and generated more than $3 billion in revenue globally in 2008. Access believes that ProLindac, as a well-tolerated and active DACH plat
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story
2. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
3. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
4. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
5. First U.S. Patients Enrolled in the REALISM Continued Access Study
6. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
7. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
8. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
9. Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
10. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
11. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-Fi... ALXA ) announced today that its corporate present...Piper Jaffray Health Care Conference on Wednesday,...presentation will be webcast from The New York Pal...mas B. King, Alexza President and CEO. ,, To ...
(Date:11/19/2009)... , CAMBRIDGE, Mass., Nov. 19 L... molecule microarray technology to find drugs agai...s raised $1M in seed financing led by incTANK Vent... its initial discovery campaign that will screen o...his investment, incTANK Ventures General Partner C...
(Date:11/19/2009)... , SCHAUMBERG, Ill., Nov. 19 ...e, PACS-neutral healthcare image management soluti...nt to provide a combined PACS- neutral archive sol..., Data Distributing, an international leader in pr...olutions to the medical industry. Under the agree...
Breaking Medicine Technology:Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 4Research Seeks Cause of Preeclampsia 56807 1Research Seeks Cause of Preeclampsia 56807 2Heavy drinking colleges showing no improvements 56803 1Heavy drinking colleges showing no improvements 56803 2SNM applauds FDAs decision to approve Zevalin 56799 1SNM applauds FDAs decision to approve Zevalin 56799 2
...N FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medic...growing problem of,hospital-acquired gram-negative...d-amikacin), which is a product candidate being,de...ults of a Phase 2a clinical trial evaluating the u...cally ventilated,patients with hospital-acquired g...
...LBOURNE, Australia & MENLO PARK, Calif.--(BUSI...ls (ASX: CXS, NASDAQ: CXSP) notes,the publication ...trategy for Ceflatonin(R) (homoharringtonine). The... Philadelphia-positive leukemias",by researchers S...,Bologna, Italy (Haematologica Volume 92, pages 40...
Other Medicine Technology:Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3
(Date:11/20/2009)..., QUINCY, Mass., Nov. 20 Followin...rket Company removed from sale Shedd,s Country Cro... and Shedd,s Country Crock ® Side Dishes DELU...allergen. ,, The following code dates and UPCs... Side Dishes DELUXE Cheddar Broccoli Rice 21 oz, U...
(Date:11/20/2009)..., CHICAGO, Nov. 20 The... U.S. Food and Drug Administration (FDA) to establ...g chemicals. ,, Citing concern about the safet...d without the benefit of professional consultation... that the application of chemically based tooth wh...
(Date:11/20/2009)..., WINSTON-SALEM, N.C., Nov. 20 /PRNewswire-USNews...on a mission to redefine what it means to be "happ... counselor with a specialty in family counseling a...orest University, Gladding says research shows tha...to sadness and even depression during the holidays...
(Date:11/20/2009)...torial published online November 20 in the Journa...exaggerated fears and hopes that often appear in n...vides guidance for both the media and journals to ...M.D., M.S., and Steven Woloshin, M.D., M.S., of Ce...nstitute for Health Policy and Clinical Practice i...
(Date:11/20/2009)...le, Washington) November 20, 2009Emergency medical...ss an estimated 350,000 cardiac arrests each year....ardiac arrest survive. Better quality cardiopulmo...MS providers may be associated with better patient...ROC) is the largest clinical research network to s...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...s have found that PG-13 rated films are not safe f...tive effect on them. The PG-13 rating strongly cau...t be inappropriate for children, but the rating st... at University of California, Los Angeles (UCLA). ...
...r-old wait of the Zhimomi family living in Nagalan...fter nearly 20 years since India got its first tes...d to deliver a test tube baby. Akheli succ...gion but all in vain. They ultimately landed at th...
...a continued to reel under a scorching June sun wit...rees Celsius Friday and Sri Ganganagar in Rajastha...d that rain clouds were nowhere in sight. ...n north India are experiencing high temperatures. ...
...have a million less AIDS patients than has been wi...ased survey whose findings were reported here. ... Melinda Gates Foundation and carried out under in... An official United Nations 2006 estimated that...
... most often-used classroom approaches for teaching...ted, until now. With a $3 million federal grant, ...rsity of North Carolina at Chapel Hill will soon b...nt center, which will help states incorporate effe...
...t clear why overweight elderly adults have low lev...hers at the Jean Mayer USDA Human Nutrition Resear...) have found that lack of sun exposure may not acc...xyvitamin D, the storage form of vitamin D, compar...
Other Medicine News:Health News:PG-13 Rated Films Adversely Expose Kids to Violence 2Health News:India Has a Million Less AIDS Cases Than Believed: Study 2Health News:FPG Receives $8 Million for Autism Research 2Health News:Lack of Sun Does Not Explain Low Vitamin D in Elderly Who are Overweight 2
... Drug Monitoring Market in 1981 with the introduct...es technology known as FPIA (Fluorescence Polariza...ion in a patient. Therapeutic Drugs, used in the t...rrow therapeutic range requiring close monitoring ...
Architect i2000SR
ADVIA Centaur Immunoassay System
UniCel DxI 800
Medicine Products: